Elevian Raises $40M Series A
18 Sep, 2021
– Disc Medicine from Cambridge MA develops therapeutic candidates for hematology.
– Series B $90M round was led by OrbiMed and attracted new investor – Arix Bioscience as well as existing investors Atlas Venture, Novo Holdings and Access Biotechnology.
– The new investment will be aimed at developing the company’s hematology pipeline of therapeutic candidates.